Highlights from Vivos Therapeutics' Financial Update
Vivos Therapeutics, Inc. has unveiled its financial performance for the second quarter of 2025, marking a period of strategic growth and development. A notable highlight in the company's journey was the acquisition of The Sleep Center of Nevada, which is already making a positive impact through strong patient demand for Vivos’ innovative treatments for obstructive sleep apnea (OSA).
Operational Developments
Kirk Huntsman, Chairman and Chief Executive Officer of Vivos, emphasized the significance of this quarter, noting the shift in the company's approach. By acquiring The Sleep Center of Nevada, Vivos is transitioning from a model that relied heavily on dentist partnerships for revenue towards a more integrated model that focuses on direct relationships with patients. This change is expected to open new revenue streams from both diagnostics and treatments.
Financial Summary for Q2 2025
For the second quarter of 2025, Vivos reported revenues of $3.8 million, a decrease compared to $4.1 million in the same period of 2024. This decline aligns with the company’s strategy of focusing on the sleep center model, which contributed approximately $500,000 in diagnostic testing revenue within a short timeframe post-acquisition. While the transition has affected immediate revenue, it is seen as a vital step toward sustainable growth.
Gross Profit and Margin Performance
The gross profit for the quarter stood at $2.1 million, reflecting a decrease from $2.7 million year-over-year. The gross margin also fell from 65% to 55%, primarily due to adjustments in pricing and changes in the product mix during the transition phase. These figures indicate the adjustments Vivos is making to optimize its new market strategy.
Increased Operating Expenses
Operating expenses surged to $7.0 million in Q2 2025, up from $4.6 million a year earlier. This rise is attributed to increased administrative costs related to the acquisition and integration of SCN, alongside other operational expenses. Despite the short-term financial pressures, Vivos remains optimistic about its long-term outlook.
Future Plans and Strategic Directions
Vivos Therapeutics is actively exploring further opportunities for growth. The company is implementing a refined practice management model for sleep providers that do not wish to sell but want to offer Vivos’ comprehensive OSA treatment options. This approach aims to broaden the reach of its innovative treatments beyond acquisitions.
Expansion Through Partnerships
On July 14, 2025, Vivos established its first management agreement with MISleep Solutions LLC. This partnership allows Vivos to provide its suite of treatments at a joint facility in Auburn Hills, Michigan. By holding a majority stake in this arrangement, Vivos aims to facilitate its business model expansion and continue its strategic growth initiatives.
Investor Engagement and Outlook
The management team at Vivos encourages stakeholders to join the upcoming conference call, where they will further discuss the implications of their new strategies for future revenue growth and cash management. The team intends to share insights regarding operational efficiencies and plans to optimize service delivery.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) focuses on innovative solutions for sleep-related breathing disorders linked to dental and facial abnormalities. Their FDA-approved devices offer hope for patients suffering from OSA and its related complications. Since its inception in 2016, Vivos has sought to revolutionize treatment protocols and expand access to effective sleep apnea solutions.
Frequently Asked Questions
What is Vivos Therapeutics' primary focus?
Vivos Therapeutics focuses on the development and commercialization of treatments for sleep-related breathing disorders, particularly obstructive sleep apnea.
What recent acquisition did Vivos complete?
Vivos recently acquired The Sleep Center of Nevada, marking a significant change in their operational strategy.
How did revenues compare in Q2 2025 to the previous year?
The company reported revenues of $3.8 million in Q2 2025, a decrease from $4.1 million in Q2 2024.
What impact has the acquisition had on Vivos' revenue streams?
The acquisition is expected to enhance revenue through direct patient engagement and diagnostics, though immediate results reflected a transition period.
What are future plans for Vivos Therapeutics?
Vivos plans to expand its partnerships with sleep providers while continuing to optimize its operational model for better service delivery.
